• Surendra H Bodakhe
  • Sanjay Kumar Gupta


Non-alcoholic fatty liver diseases (NAFLD) are the most occurring chronic liver diseases caused by hepatic manifestation of metabolic syndromes
like insulin resistance in Type-2 diabetes, obesity and hyperlipidemic condition. Indian men have a high prevalence of NAFLD. Genetic factor is also
an important consideration for NAFLD. The core aim of this study is to focus on non-invasive biochemical markers for diagnosis of NAFLD as an
alternative to liver biopsy. Biopsy is the gold standard for NAFLD; however a variety of studies powerfully suggest that due to the limitation and risk
of biopsy, as well as improvement of the diagnostic accuracy of biochemical markers, biopsy should no longer be considered obligatory. Thus, due to
the limitation of liver biopsy, numerous biomarkers has been developed recently, which may provide more accurate results than an inferior quality
liver biopsy. Some important biomarkers are caspase-cleaved cytokeratin-18, breath biomarker, circulating microRNAs, abdominal ultrasound,
adipocytokines, etc.
Keywords: Adipocytokines, Cytokeratin-18, Liver biopsy, MicroRNAs, Non-alcoholic fatty liver diseases, Non-invasive biomarkers



Download data is not yet available.


Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006;82(967):315-22.

Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010;362(12):1082-9.

Clark JM, Diehl AM. Nonalcoholic fatty liver disease: An underrecognized cause of cryptogenic cirrhosis. JAMA 2003;289(22):3000-4.

Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, et al. Assessment of liver fibrosis: Noninvasive means. Saudi J Gastroenterol 2008;14(4):163-73.

Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol 2008;32 6 Suppl 1:22‑39.

Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, et al. Diagnostic value of biochemical markers (FibroTest‑FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6:6.

Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study. Hepatology 2009;50(4):1072-8.

Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011;43(8):617-49.

Liangpunsakul S, Chalasani N. Is hypothyroidism a risk factor for non‑alcoholic steatohepatitis? J Clin Gastroenterol 2003;37(4):340-3.

Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome. Cleve Clin J Med 2008;75(10):721-8.

Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005;4:10.

Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 1999;45 Suppl 4:IV1‑IV11.

Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: A systematic review and meta-analysis. Gut 2008;57(11):1592-6.

Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 1993;118(2):96-8.

Pasha T, Gabriel S, Therneau T, Dickson ER, Lindor KD. Cost-effectiveness of ultrasound-guided liver biopsy. Hepatology 1998;27(5):1220-6.

Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: An audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995;36(3):437-41.

Strassburg CP, Manns MP. Approaches to liver biopsy techniques – Revisited. Semin Liver Dis 2006;26(4):318-27.

Froehlich F, Lamy O, Fried M, Gonvers JJ. Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig Dis Sci 1993;38(8):1480-4.

Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97(10):2614-8.

Agence Nationale d’Accréditation et d’Evaluation en Santé (ANAES). Consensus conference. Treatment of hepatitis C. Gastroenterol Clin Biol 2002;26:B303-20.

Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008;134(6):1670-81.

Radu CI, CriÅŸan DA, Grigorescu M. How can we predict steatosis using biochemical markers (SteatoTest and Fatty liver index)? Hum Vet Med 2011;3(2):89-96.

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41(6):1313-21.

Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33.25. Parsian H, Rahimipour A, Nouri M, Somi MH, Qujeq D. Assessment of liver fibrosis development in chronic hepatitis B patients by serum hyaluronic acid and laminin levels. Acta Clin Croat 2010;49(3):257-65.

Stauber RE, Lackner C. Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. World J Gastroenterol 2007;13(32):4287-94.

Leroy V. Other non-invasive markers of liver fibrosis. Gastroenterol Clin Biol 2008;32 6 Suppl 1:52-7.

Halfon P, Bourlière M, Pénaranda G, Deydier R, Renou C, Botta‑Fridlund D, et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 2005;4:6.

Timpl R, Rohde H, Robey PG, Rennard SI, Foidart JM, Martin GR. Laminin – A glycoprotein from basement membranes. J Biol Chem 1979;254(19):9933-7.

Niemelä O, Risteli J, Blake JE, Risteli L, Compton KV, Orrego H. Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology 1990;98(6):1612-9.

Körner T, Kropf J, Gressner AM. Serum laminin and hyaluronan in liver cirrhosis: Markers of progression with high prognostic value. J Hepatol 1996;25(5):684-8.

Solga SF, Alkhuraishe A, Cope K, Tabesh A, Clark JM, Torbenson M, et al. Breath biomarkers and non-alcoholic fatty liver disease: Preliminary observations. Biomarkers 2006;11(2):174-83.

Banasch M, Ellrichmann M, Tannapfel A, Schmidt WE, Goetze O. The non-invasive (13)C-methionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in non‑alcoholic steatohepatitis. Eur J Med Res 2011;16(6):258-64.

Millonig G, Praun S, Netzer M, Baumgartner C, Dornauer A, Mueller S, et al. Non-invasive diagnosis of liver diseases by breath analysis using an optimized ion-molecule reaction-mass spectrometry approach: A pilot study. Biomarkers 2010;15(4):297-306.

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova‑Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105(30):10513-8.

Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: A new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010;101(10):2087-92.

Brase JC, Wuttig D, Kuner R, Sültmann H. Serum microRNAs as non‑invasive biomarkers for cancer. Mol Cancer 2010;9:306.

Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011;6(8):e23937.

Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3(2):87-98.

Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005 1;438:685-9.

Xu H, He JH, Xiao ZD, Zhang QQ, Chen YQ, Zhou H, et al. Liver‑enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 2010;52(4):1431-42.

Lewis AP, Jopling CL. Regulation and biological function of the liver‑specific miR-122. Biochem Soc Trans 2010;38(6):1553-7.

Beretta L. Comparative analysis of the liver and plasma proteomes as a novel and powerful strategy for hepatocellular carcinoma biomarker discovery. Cancer Lett 2009;286(1):134-9.

Ong SE, Mann M. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 2005;1(5):252-62.

Tao WA, Aebersold R. Advances in quantitative proteomics via stable isotope tagging and mass spectrometry. Curr Opin Biotechnol 2003;14(1):110-8.

Wu S, Kaiser NK, Meng D, Anderson GA, Zhang K, Bruce JE. Increased protein identification capabilities through novel tandem MS calibration strategies. J Proteome Res 2005;4(4):1434-41.

Li S, Liu X, Wei L, Wang H, Zhang J, Wei H, et al. Plasma biomarker screening for liver fibrosis with the N-terminal isotope tagging strategy. Sci China Life Sci 2011;54(5):393-402.

Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123(3):745-50.

Mottin CC, Moretto M, Padoin AV, Swarowsky AM, Toneto MG, Glock L, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004;14(5):635-7.

Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis 2007;11(1):37-54, viii.

Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol 2007;102(12):2716-7.

Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115(5):911-9.

Wang Y, Zhou M, Lam KS, Xu A. Protective roles of adiponectin in obesity-related fatty liver diseases: Mechanisms and therapeutic implications. Arq Bras Endocrinol Metabol 2009;53(2):201-12.

Friedman JM, Leibel RL, Siegel DS, Walsh J, Bahary N. Molecular mapping of the mouse ob mutation. Genomics 1991;11(4):1054-62.

Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35(2):373-9.

Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology 2002;35(2):367‑72.

Thomas T, Burguera B, Melton LJ 3rd, Atkinson EJ, O’Fallon WM, Riggs BL, et al. Relationship of serum leptin levels with body composition and sex steroid and insulin levels in men and women. Metabolism 2000;49(10):1278-84.

Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: Correlations with insulin resistance. Eur J Endocrinol 2003;149(4):331‑5.

Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity? Hepatology 2002;36(2):403-9.

Romanowska A, Lebensztejn DM, Skiba E, Tarasów E, Kaczmarski M. Retinol binding protein-4 as a serum biomarker of intrahepatic lipid content in obese children – Preliminary report. Acta Biochim Pol 2011;58(1):35-8.

Nobili V, Alkhouri N, Alisi A, Ottino S, Lopez R, Manco M, et al. Retinol-binding protein 4: A promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7(5):575-9.

Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436(7049):356-62.

Milner KL, van der Poorten D, Xu A, Bugianesi E, Kench JG, Lam KS, et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 2009;49(6):1926-34.

Cengiz C, Ardicoglu Y, Bulut S, Boyacioglu S. Serum retinol-binding protein 4 in patients with nonalcoholic fatty liver disease: Does it have a significant impact on pathogenesis? Eur J Gastroenterol Hepatol 2010;22(7):813-9.

Steppan CM, Lazar MA. The current biology of resistin. J Intern Med 2004;255(4):439-47.

Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005;111(7):932-9.

Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology 2008;15(2):91-101.

Fitzpatrick E, Mitry RR, Quaglia A, Hussain MJ, DeBruyne R, Dhawan A. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr 2010;51(4):500-6.

Ribeiro PS, Cortez-Pinto H, Solá S, Castro RE, Ramalho RM, Baptista A, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004;99(9):1708-17.

Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006;44(1):27-33.

Sanyal AJ. Mechanisms of disease: Pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005;2(1):46-53.

Hägg M, Bivén K, Ueno T, Rydlander L, Björklund P, Wiman KG, et al. A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs 2002;20(3):253-9.

Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004;64(5):1751-6.74. Graversen JH, Madsen M, Moestrup SK. CD163: A signal receptor scavenging haptoglobin-hemoglobin complexes from plasma. Int J Biochem Cell Biol 2002;34(4):309-14.

Madsen M, Graversen JH, Moestrup SK. Haptoglobin and CD163: Captor and receptor gating hemoglobin to macrophage lysosomes. Redox Rep 2001;6(6):386-8.

Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 1999;7(2):169-77.

Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest 2003;111(12):1805-12.

Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: Molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005;288(5):H2031-41.

Liu SL, Cheng CC, Chang CC, Mai FD, Wang CC, Lee SC, et al. Discovery of serum biomarkers of alcoholic fatty liver in a rodent model: C-reactive protein. J Biomed Sci 2011;18:52.

Taouli B, Ehman RL, Reeder SB. Advanced MRI methods for assessment of chronic liver disease. AJR Am J Roentgenol 2009;193(1):14-27.

Harrison SA, Bacon BR. Relation of hemochromatosis with hepatocellular carcinoma: Epidemiology, natural history, pathophysiology, screening, treatment, and prevention. Med Clin North Am 2005;89(2):391-409.

Liangpunsakul S, Chalasani N. Is hypothyroidism a risk factor for non‑alcoholic steatohepatitis? J Clin Gastroenterol 2003;37(4):340-3.

Zhang J, Sun H, Chen L, Zheng J, Hu X, Wang S, et al. Relationship between serum TSH level with obesity and NAFLD in euthyroid subjects. J Huazhong Univ Sci Technolog Med Sci 2012;32(1):47-52.

Fung JY, Lai CL, Yuen MF. Clinical application of transient elastography (Fibroscan) in liver diseases. Med Bull 2009;14:22-5.

Fan XF, Deng YQ, Ye L, Li YD, Chen J, Lu WW, et al. Effect of Xuezhikang Capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia. Chin J Integr Med 2010;16(2):119-23.

Kruger FC, Daniels CR, Kidd M, Swart G, Brundyn K, van Rensburg C, et al. APRI: A simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J 2011;101(7):477-80.

Bodakhe SH, Ram A. Hepatoprotective properties of Bauhinia variegata bark extract. Yakugaku Zasshi 2007;127(9):1503-7.



How to Cite

Bodakhe, S. H., and S. K. Gupta. “DIAGNOSTIC METHODS FOR NON-ALCOHOLIC FATTY LIVER DISEASES ALTERNATIVE TO LIVER BIOPSY: A REVIEW”. Asian Journal of Pharmaceutical and Clinical Research, vol. 8, no. 2, Mar. 2015, pp. 54-59, https://innovareacademics.in/journals/index.php/ajpcr/article/view/4989.



Review Article(s)